CLINUVEL Showcases SCENESSE® Efficacy at EADV Symposium

Clinuvel Pharmaceuticals ( (AU:CUV) ) just unveiled an announcement.

CLINUVEL Pharmaceuticals has presented long-term data on their drug SCENESSE® at the European Academy of Dermatology and Venereology Symposium, highlighting its safety and effectiveness in treating erythropoietic protoporphyria (EPP) and hepatoerythropoietic porphyria (HEP). The presentation underscores the drug’s positive impact on patient quality of life and its consistent safety profile, reinforcing CLINUVEL’s position as a leader in photomedicine. The announcement also emphasizes Italy’s pioneering role in EPP treatment, with SCENESSE® being administered since 2008 and the country having the largest EPP treatment network in Europe.

The most recent analyst rating on (AU:CUV) stock is a Buy with a A$46.35 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.

More about Clinuvel Pharmaceuticals

CLINUVEL PHARMACEUTICALS LIMITED is a global specialty pharmaceutical group focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening acute disorders. They are pioneers in photomedicine and melanocortin peptides, with their lead therapy, SCENESSE® (afamelanotide 16mg), approved for preventing phototoxicity in erythropoietic protoporphyria (EPP) patients. The company operates in Europe, Singapore, and the USA, with headquarters in Melbourne, Australia.

Average Trading Volume: 163,471

Technical Sentiment Signal: Sell

Current Market Cap: A$532.8M

For a thorough assessment of CUV stock, go to TipRanks’ Stock Analysis page.